Amplify CWP International Enhanced Dividend Income ETF (ARCA: IDVO)

最新ニュース Amplify CWP International Enhanced Dividend Income ETF (ARCA:IDVO)

Amplify CWP International Enhanced Dividend Income ETF

Financial Services

Energy

Consumer Cyclical

Healthcare

Basic Materials

Communication Services

Technology

Consumer Defensive

Industrials

The Fund invests at least 80 Percent of its net assets (plus borrowings for investment purposes) in dividend-paying U.S. exchange-traded American depositary receipt (ADR) securities (Equity Securities) that are organized or located outside of the United States and will opportunistically utilize an option strategy consisting of writing (selling) U.S. exchange-traded covered call option contracts on such Equity Securities.

Invesco Government & Agency Portfolio, Institutional Class

Mitsubishi UFJ Financial Group Inc ADR

Sap S.e., ADR

Relx Plc, ADR

Icici Bank Ltd. ADR

Sumitomo Mitsui Financial Group Inc Adr Each Repr 1/5 Ord Npv

Agnico Eagle Mines Ltd

Ferrari N.V. Common Shares Of Fe New N V To Be Renamed Ferrari N V Post

TotalEnergies Se ADR

Crh Plc

Barclays Plc-adr

Siemens AG ADR

Taiwan Semiconductor Manufacturing Co. Ltd. Sponsored ADR

Enbridge Inc. Cumulative Redeemable Pfd

RWE AG PK

Amplify International Enhanced Dividend Income ETF

Asia

News

Emerging Markets

Eurozone

General

DIVD

IDVO

トヨタ自動車（Toyota Motor Corp.）（NYSE：TM）の乗用車認証には矛盾が見つかり、これらの誤差は62ヶ国と地域（欧州連合を含む）が従う重要な規制である国際基準にも違反していることが明らかになりました。

トヨタの乗用車認証違反　影響は世界に波及

Hong Kong leading logistics solutions provider New Century Logistics (BVI) Limited (hereinafter referred to as "New Century") today announced the formal signing of a Memorandum of Understanding ("MOU") with Silk Way Airlines Limited (hereinafter referred to as "Silkway"), a well-known air cargo airline in Hong Kong. Both parties will explore innovative solutions in the international air freight logistics sector based on resource sharing and complementary strengths, aiming to enhance global supply chain efficiency for their clients.
Stronger collaboration
According to the MOU, New Century and Silkway will conduct in-depth cooperation in the following directions:
<ul>
<li>Joint development of international air freight logistics solutions: integrating New Century's global logistics network with Silkway's air cargo resources to provide end-to-end efficient transportation services for cross-border trading enterprises.</li>
<li>Market intelligence and logistics best practices sharing: optimize route planning, cost control and risk management capabilities through data exchange and experience sharing.</li>
<li>Collaborative marketing and brand promotion: Joint promotion of services offered by both parties to expand business coverage in Asia Pacific, Europe and emerging markets.</li>
<li>Customer experience upgrade: build a seamless logistics service system, improve the transparency of cargo tracking and delivery timeliness.</li>
</ul>

NCEW

New Century Logistics Signs MOU With Silk Way Airlines To Explore Innovative Solutions In International Air Freight Logistics Sector

Wells Fargo analyst Praneeth Satish maintains Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Overweight and raises the price target from $69 to $71.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Nextracker, Raises Price Target to $71

FRSX

Trading Halt: Halt status updated at 8:35:00 AM ET: Quotation Resumption: News and Resumption Times

Evercore ISI Group analyst David Raso maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Outperform and lowers the price target from $451 to $419.

Evercore ISI Group Maintains Outperform on Cummins, Lowers Price Target to $419

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --
-- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
-- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair --
-- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --
CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a strategic restructuring, including the deprioritization of its Chronic Granulomatous Disease (CGD) programs, as well as a cost and workforce reduction to focus on its liver franchise and programs funded through external partnerships.
Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD), with initial clinical data from both programs expected in 2027. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources.
Also today, Prime Medicine announced that Keith Gottesdiener, M.D., has decided to step down as Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Allan Reine, M.D., Prime Medicine's Chief Financial Officer (CFO), has been named CEO and member of the Board of Directors and Jeff Marrazzo, member of the Company's Board of Directors, has been named Executive Chair.

Management

PRME

Prime Medicine Implementing Cost Cutting Measures To Significantly Reduce Cash Needs In Advance Of Key Data Inflection Points; Allan Reine, CFO, To Succeed Keith Gottesdiener, As CEO; Jeff Marrazzo, Member Of The Board Of Directors, Named Executive Chair

Patrick Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) ("Patrick" or the "Company"), a leading component solutions provider for the Outdoor Enthusiast and Housing markets, announced that Jake Petkovich will rejoin Patrick as President – Marine, succeeding Rick Reyenger, effective May 19, 2025. Mr. Reyenger will remain with the Company and move to a strategic advisory role to support continuity and ensure a smooth and seamless transition across the Company's Marine businesses.

PATK

Patrick Industries Says Jake Petkovich To Rejoin As President – Marine, Succeeding Rick Reyenger, Effective May 19, 2025

Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) sees Q2 sales of $181.487 million-$194.441 million.

Guidance

Niu Tech expects Q2 2025 Revenue between RMB 1.317B and RMB 1.411B, YoY increase of 40% to 50%.

The renewal from a key client demonstrates strong loyalty, while a new major deal reflects continued growth momentum heading into FY2026.
BEIJING, May 19, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTSS#NASDAQ">DTSS</a>) ("Datasea" or the "Company"), a Nevada-based technology company specializing in acoustic high-tech products and 5G+AI multimodal digital solutions, today announced that its subsidiaries have signed two new service contracts totaling up to $100 million for the provision of 5G-AI multimodal digital services over a 12-month period. The customers include long-term partner Qingdao Ruizhi Yixing Information Technology Co., Ltd. ("Qingdao Ruizhi Yixing") and a new key client, Qingdao Dong'an Information Technology Co., Ltd.
Under the terms of the agreements, Datasea will deliver customized 5G-AI digital services, including data Top-up solutions and AI-powered communication tools, to both Qingdao Ruizhi Yixing and Qingdao Dong'an. Each contract is valued up to $50 million, representing a strong vote of recognition and confidence in the performance and value of Datasea's 5G-AI solutions.

DTSS

Datasea Subsidiaries Sign Two New Service Contracts Totalling Up To $100M For Provision Of 5G-AI Multimodal Digital Services Over 12-Month Period

TransDigm Group and Servotronics Announce ~$110M Definitive Merger Agreement For Servotronics To Become Wholly Owned Subsidiary Of TransDigm

Evercore ISI Group analyst David Raso maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a In-Line and lowers the price target from $375 to $373.

Evercore ISI Group Maintains In-Line on Caterpillar, Lowers Price Target to $373

Evercore ISI Group analyst Michael Binetti maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $70.

BIRK

Evercore ISI Group Maintains Outperform on Birkenstock Holding, Raises Price Target to $70

Biotech

VNRX

VolitionRx Publishes  "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" In BMC Veterinary Research

Wells Fargo analyst Zachary Fadem maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Equal-Weight and lowers the price target from $85 to $75.

Wells Fargo Maintains Equal-Weight on Best Buy Co, Lowers Price Target to $75

Market-Moving Exclusives

Exclusives

GTBP

EXCLUSIVE: GT Biopharma Tells Benzinga 'The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts'

EXCLUSIVE: GT Biopharma Tells Benzinga 'Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2'

GT Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is a second-generation TriKE therapeutic targeting relapsed or refractory CD33-expressing hematologic malignancies.
GT Biopharma specializes in immuno-oncology therapies using its proprietary TriKE NK cell engager platform and holds an exclusive global license with the University of Minnesota for its development and commercialization.
No safety or tolerability issues were observed in Cohort 1, allowing progression to the next cohort, the company said.
Early biomarker analysis from Cohort 1 patients indicates increased immunologic activity, suggesting activation and expansion of natural killer (NK) cells.
The trial, which may include up to 14 patients across seven cohorts, involves two-week dosing blocks over a four-month period and will evaluate safety, pharmacokinetics, pharmacodynamics, NK cell expansion, and clinical activity.
The company said that it will release detailed results in 2025.
In January, the company had initiated patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with hematological malignancies.
Price Action: GTBP stock traded higher by 0.90% to $2.26 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns" target="_blank" rel="noreferrer noopener">Moody's Downgrades U.S. Credit Rating Over Debt, Deficit Concerns</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Health Care

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

EXCLUSIVE: GT Biopharma Tells Benzinga Co. Advances GTB-3650 Phase I Trial To Cohort 2 Following Successful Initial Human Dosing And Evidence Of Early Immune Activation Signals

UHGWW

Trading Halt: Halt status updated at 8:30:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Zachary Fadem maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Overweight and raises the price target from $3850 to $4200.

Wells Fargo Maintains Overweight on AutoZone, Raises Price Target to $4200

Economist Peter Schiff has sharply criticized Treasury Secretary Scott Bessent for downplaying the role of President Donald Trump's tax cuts in the recent Moody's downgrade of the U.S. sovereign credit rating, instead pinning the blame on the Joe Biden administration.
What Happened: Schiff's comments, posted on X, come amid heated debates over the nation's fiscal health as the U.S. debt continues to spiral, now standing at a staggering $36.22 trillion.
In his post, Schiff highlighted that Moody's specifically cited the extension of Trump's 2017 tax cuts as a key reason for its decision to <a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns">downgrade the U.S. credit rating</a> from Aaa to Aa1 on May 16, 2025.
However, Bessent, in television interviews earlier on May 18, dismissed Moody's action as a "<a href="https://www.benzinga.com/markets/25/05/45484954/treasury-secretary-bessent-addresses-moodys-downgrade-and-tariff-impact-n-walmart">lagging indicator</a>," arguing that the downgrade reflected the Biden administration's spending policies rather than the tax cuts.
Bessent further claimed that the tax bill, which advanced through the House Budget Committee on May 18, would spur economic growth sufficient to outpace the nation's debt obligations. "I think that Moody's is a lagging indicator," Bessent said <a href="https://www.nbcnews.com/politics/trump-administration/scott-bessent-calls-moodys-lagging-indicator-us-credit-downgrade-rcna207535">on</a> NBC News' Meet the Press, adding, "That's what everyone thinks of credit agencies."
Schiff pushed back strongly against Bessent's narrative, accusing him of sidestepping the real issue.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Scott Bessent blamed the Moody&#39;s downgrade on the Biden administration. Yet Moody&#39;s specifically cited extending Trump&#39;s tax cuts as the reason for its decision. Bessent dismissed the downgrade as a lagging indicator. It&#39;s only lagging in that Moody&#39;s should have acted sooner.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1924412660730273973?ref_src=twsrc%5Etfw">May 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distorti">Trump&#8217;s Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight &#8216;Racket,&#8217; Pricing Distortion</a>
Why It Matters: The downgrade, which ended Moody's century-long pristine rating of the U.S. since 1919, was attributed to concerns over the nation's growing debt pile and the projected increase in fiscal deficits.
According to Moody's, the extension of these tax cuts—originally set to expire in 2025—would exacerbate the deficit, with nonpartisan analysts estimating an additional $3 trillion to $5 trillion added to the national debt over the next decade.
The agency also warned that the U.S. debt-to-GDP ratio could climb to 134% by 2035 if current trends persist.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.98% to $588.40, while the QQQ declined 1.40% to $514.19, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45465955/ark-invest-takes-swipe-at-mstr-mara-says-bitcoin-treasury-companies-dont-make-sense-fundin" target="_blank" rel="noreferrer noopener">Ark Invest Expert Takes Swipe At MSTR, MARA, Says ‘Bitcoin Treasury Companies Don't Make Sense:' ‘Funding Purchases With Debt…Seems Like A Recipe For Disaster'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Markets

ETFs

Peter Schiff Slams Scott Bessent For Ignoring Trump's Tax Cuts In Moody's Downgrade, Blaming Biden Instead: 'It's Only Lagging In That Moody's Should Have Acted Sooner'

Press Releases

Amplify ETFs Launches the Amplify CWP Growth & Income ETF (NYSE Arca: QDVO)

DIVO

QDVO

トヨタ自動車（Toyota Motor Corp.）（NYSE：TM）の乗用車認証には矛盾が見つかり、これらの誤差は62ヶ国と地域（欧州連合を含む）が従う重要な規制である国際基準にも違反していることが明らかになりました。
これらの調査結果の意味は、日本国内のみならず、欧州連合を含む62カ国と地域が適用している国際基準にも影響を与える可能性があります。
規制当局が自動車メーカーに対して同様の措置を取ることを検討する可能性があるため、これらの発見の意義が日本を越えて広がる可能性があると<a href="https://www.bloomberg.com/news/articles/2024-06-11/toyota-s-faulty-certifications-also-breach-un-rules-yomiuri?srnd=industries-v2&amp;sref=TBDibEcD">ブルームバーグ</a>が報じています。
今月初旬、日本の国土交通省は、この問題に対処するため、6つのモデルの販売と納入を停止しました。そのうち3つがトヨタの製品で、Corolla Fielder、Corolla Axio、Yaris Cross が含まれています。
この措置は、トヨタの他にもいくつかの自動車メーカーが同様の行動を取る可能性があるという動きに続くものです。
この対策は、歩行者安全テスト中に安全データを改竄し、他のいくつかのモデルについては衝突テストで非標準車を使用していたことが判明した社内調査によって行われました。
トヨタの社長豊田章男は、この危機に応じて、この試験は日本の規制で求められる以上に厳しい条件のもとで行われたというコメントを発表し、また自動車は安全に運転することができると述べました。
さらに読む：<a href="https://www.benzinga.com/markets/equities/24/05/39036874/toyota-subaru-mazda-aim-for-carbon-neutral-future-in-engine-development-details">トヨタ、スバル、マツダがエンジン開発で炭素ニュートラルな未来を目指す</a>
ただし、強調すると、彼は認証プロセスにおける重大な失敗があったことを認め、それに対して謝罪しました。
豊田は6月3日の記者会見で、「我々は、必要な予防措置を取らずに、認証プロセスを無視して自動車の量産を行ってしまった」と述べました。
トヨタは、この問題が年間約13万台の車両を生産している2つの生産ラインに影響を及ぼすと発表しました。
この問題が発生したのは、トヨタが来週、株主総会に向けて準備を進めている重要な時期でもあります。 2023年、トヨタは世界中で1,100万台以上の乗用車を製造・販売しました。
トヨタの株は過去12か月で36%上昇しています。投資家は、Amplify CWP International Enhanced Dividend Income ETF（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/IDVO#NYSE">IDVO</a>）とAltrius Global Dividend ETF（NASDQ：DIVD）を通じて株に露出することができます。
株価の変動：月曜日、TMの株は0.80％上昇し、208.02ドルで取引を終了しました。

Comments

Amplify CWP International Enhanced Dividend Income ETF

ニュース

最新ニュース Amplify CWP International Enhanced Dividend Income ETF (ARCA:IDVO)

木曜日, 6 13, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル